Ignite Creation Date:
2024-05-06 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05358821
Status:
COMPLETED
Last Update Posted:
2024-05-13
First Post:
2022-04-27
Brief Title:
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntingtons Disease
Sponsor:
Sage Therapeutics
Organization:
Sage Therapeutics
Study Overview
Official Title:
A 28-Day Randomized Placebo-Controlled Double-Blind Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntingtons Disease
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntingtons Disease HD and healthy participants HP with respect to measures of cognitive performance
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None